Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
Status:
Recruiting
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Congenital toxoplasmosis is an infection caused by the parasitic organism
Toxoplasma gondii, and it may be passed from an infected mother to her unborn child. The
mother may have mild symptoms or no symptoms; the fetus, however, may experience damage to
the eyes, nervous system, skin, and ears. The newborn may have a low birth weight, enlarged
liver and spleen, jaundice, anemia, petechiae, and eye damage. Giving the antiparasitic drugs
pyrimethamine and sulfadiazine is standard treatment for congenital toxoplasmosis, but it is
not yet known which regimen of pyrimethamine is most effective for the disease.
PURPOSE: Randomized phase IV trial to determine which regimen of pyrimethamine is most
effective when combined with sulfadiazine and leucovorin in treating patients who have
congenital toxoplasmosis.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)